# A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

> **NCT02663089** · PHASE1 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 6 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** [14C]-GSK961081 solution for IV infusion
- **DRUG:** [14C]-GSK961081 oral solution
- **DRUG:** GSK961081 dry powder for inhalation

## Key facts

- **NCT ID:** NCT02663089
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-08
- **Primary completion:** 2016-03-17
- **Final completion:** 2016-03-17
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663089, "A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02663089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*